Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | SI | P14410 | 3/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.34 |
| ▸ | CMA1 | P23946 | 9/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1294649 | 1.00 | MGAM (0.34) | MGAMGAASIMGAM2CMA1 | |
| SCHEMBL1294481 | 0.91 | CYP1A2 (0.34) | MGAMGAASIMGAM2GPR139 | |
| SCHEMBL1294482 | 0.91 | CYP1A2 (0.34) | MGAMGAASIMGAM2GPR139 | |
| SCHEMBL1294774 | 0.87 | CMA1 (0.40) | MGAMGAASIMGAM2CMA1 | |
| SCHEMBL1294768 | 0.87 | CMA1 (0.40) | MGAMGAASIMGAM2CMA1 | |
| SCHEMBL1295146 | 0.85 | USP1 (0.33) | MGAMGAASIMGAM2CMA1 | |
| SCHEMBL1295142 | 0.85 | USP1 (0.33) | MGAMGAASIMGAM2CMA1 | |
| SCHEMBL1294108 | 0.85 | MGAM (0.33) | MGAMGAASIMGAM2CMA1 | |
| SCHEMBL1294106 | 0.85 | MGAM (0.33) | MGAMGAASIMGAM2CMA1 | |
| SCHEMBL2313701 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062056-B2 | Aza-benzimidazolone Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| EP-2364313-B1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-20110269780-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2364313-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010030500-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269780-A1 | AZA-BENZIMIDAZOLONE CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | MGAM 369/4885GAA 5/4885SI 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.